In this episode, we sit down with Dr. Nicholas Ashton, senior director of Banner Research's Fluid Biomarker Program, to dive deep into the cutting-edge world of Alzheimer's biomarker research. We explore how advancements in diagnosing Alzheimer's without directly touching the brain are revolutionizing the field. Dr. Ashton breaks down the significance of clinical symptom analysis paired with innovative biological testing methods—ushering in a new era of Alzheimer's diagnosis. Breakthrough blood tests are creating new opportunities for earlier Alzheimer's detection, expanding beyond research to everyday clinical practices. We also discuss how these innovations are accelerating the recruitment process for clinical trials, speeding up the development of new treatments.